{'52WeekChange': -0.57394135,
 'SandP52WeekChange': None,
 'address1': 'Hemmelrather Weg 201',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 6.41,
 'askSize': 800,
 'averageDailyVolume10Day': 1900,
 'averageVolume': 2076,
 'averageVolume10days': 1900,
 'beta': 1.128488,
 'beta3Year': None,
 'bid': 6,
 'bidSize': 800,
 'bookValue': 0.678,
 'category': None,
 'circulatingSupply': None,
 'city': 'Leverkusen',
 'companyOfficers': [],
 'country': 'Germany',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 6.54,
 'dayLow': 6,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 143742208,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '49 214 87 63 290',
 'fiftyDayAverage': 6.5251713,
 'fiftyTwoWeekHigh': 15.776,
 'fiftyTwoWeekLow': 5.27,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 11263021,
 'forwardEps': -1.21,
 'forwardPE': -5.29752,
 'fromCurrency': None,
 'fullTimeEmployees': 160,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0,
 'heldPercentInstitutions': 0.00088,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/biofrontera.com',
 'longBusinessSummary': 'Biofrontera AG, a biopharmaceutical company, engages '
                        'in the development and commercialization of '
                        'pharmaceutical products for the treatment of '
                        'dermatological conditions and diseases caused '
                        'primarily by exposure to sunlight that results in sun '
                        'damage to the skin. Its principal product is Ameluz, '
                        'a prescription drug for the treatment of '
                        'lesion-directed and field-directed actinic keratosis. '
                        'The company also offers BF-RhodoLED lamp, a '
                        'photodynamic therapy for lesion-directed and '
                        'field-directed treatment of actinic keratosis; and '
                        'Belixos, an over-the-counter line of skin care '
                        'cosmetic products. In addition, it is developing '
                        'Ameluz for the treatment of field cancerization and '
                        'nodular basal cell carcinoma; BF-derm1 for the '
                        'treatment of chronic and antihistamine-resistant '
                        'urticaria; and BF-1 for the prophylactic treatment of '
                        "migraine. Further, the company's product portfolio "
                        'includes Xepi, a prescription antibiotic cream for '
                        'the treatment of impetigo; and Aktipak, a generic '
                        'drug for the treatment of acne. It offers its '
                        'products primarily in the United States, Europe, and '
                        'Israel. The company has a collaboration and '
                        'partnership agreement with Maruho Co., Ltd. '
                        'Biofrontera AG was founded in 1997 and is '
                        'headquartered in Leverkusen, Germany.',
 'longName': 'Biofrontera AG',
 'market': 'us_market',
 'marketCap': 152508000,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_139391',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 6,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '49 214 87632 0',
 'previousClose': 6.54,
 'priceHint': 2,
 'priceToBook': 9.454277,
 'priceToSalesTrailing12Months': None,
 'profitMargins': -0.33042,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 6.54,
 'regularMarketDayLow': 6,
 'regularMarketOpen': 6,
 'regularMarketPreviousClose': 6.54,
 'regularMarketPrice': 6,
 'regularMarketVolume': 627,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 22424700,
 'sharesPercentSharesOut': 0,
 'sharesShort': 697,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 576,
 'shortName': 'Biofrontera AG American Deposit',
 'shortPercentOfFloat': None,
 'shortRatio': 2.52,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'BFRA',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.762,
 'twoHundredDayAverage': 7.969151,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'ac5dfd43-eb42-3d81-aa17-a87c96168313',
 'volume': 627,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.biofrontera.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '51377'}